Previous close | 4.88 |
Open | 4.87 |
Bid | 4.99 x 200 |
Ask | 5.04 x 400 |
Day's range | 4.87 - 5.11 |
52-week range | 2.13 - 7.73 |
Volume | |
Avg. volume | 578,890 |
Market cap | 242M |
Beta (5Y monthly) | 1.31 |
PE ratio (TTM) | 11.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LOS ANGELES, April 18, 2024--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
LOS ANGELES, April 03, 2024--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES, March 20, 2024--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.